Literature DB >> 23539755

Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

Robert E Bristow1, Matthew A Powell, Noor Al-Hammadi, Ling Chen, J Philip Miller, Phillip Y Roland, David G Mutch, William A Cliby.   

Abstract

BACKGROUND: The relationship between racial and socioeconomic status (SES) disparities and the quality of epithelial ovarian cancer care and survival outcome are unclear.
METHODS: A population-based analysis of National Cancer Data Base (NCDB) records for invasive primary epithelial ovarian cancer diagnosed in the period from 1998 to 2002 was done using data from patients classified as white or black. Adherence to National Comprehensive Cancer Network (NCCN) guideline care was defined by stage-appropriate surgical procedures and recommended chemotherapy. The main outcome measures were differences in adherence to NCCN guidelines and overall survival according to race and SES and were analyzed using binomial logistic regression and multilevel survival analysis.
RESULTS: A total of 47 160 patients (white = 43 995; black = 3165) were identified. Non-NCCN-guideline-adherent care was an independent predictor of inferior overall survival (hazard ratio [HR] = 1.43, 95% confidence interval [CI] = 1.38 to 1.47). Demographic characteristics independently associated with a higher likelihood of not receiving NCCN guideline-adherent care were black race (odds ratio [OR] = 1.36, 95% CI = 1.25 to 1.48), Medicare payer status (OR = 1.20, 95% CI = 1.12 to 1.28), and not insured payer status (OR = 1.33, 95% CI = 1.19 to 1.49). After controlling for disease and treatment-related variables, independent racial and SES predictors of survival were black race (HR = 1.29, 95% CI = 1.22 to 1.36), Medicaid payer status (HR = 1.29, 95% CI = 1.20 to 1.38), not insured payer status (HR = 1.32, 95% CI = 1.20 to 1.44), and median household income less than $35 000 (HR = 1.06, 95% CI = 1.02 to 1.11).
CONCLUSIONS: These data highlight statistically and clinically significant disparities in the quality of ovarian cancer care and overall survival, independent of NCCN guidelines, along racial and SES parameters. Increased efforts are needed to more precisely define the patient, provider, health-care system, and societal factors leading to these observed disparities and guide targeted interventions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23539755      PMCID: PMC3691950          DOI: 10.1093/jnci/djt065

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  36 in total

1.  National Cancer Data Base/Surveillance Epidemiology and End Results: potential insensitive-measure bias.

Authors:  J Fanning; A Gangestad; S J Andrews
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

2.  Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization.

Authors:  Valerie McGuire; Lisa Herrinton; Alice S Whittemore
Journal:  Epidemiology       Date:  2002-03       Impact factor: 4.822

3.  Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy?

Authors:  Dana M Chase; Stacey Fedewa; Tatiana Stanisic Chou; Amy Chen; Elizabeth Ward; Wendy R Brewster
Journal:  Obstet Gynecol       Date:  2012-01       Impact factor: 7.661

4.  Ethnic differences in survival among women with ovarian carcinoma.

Authors:  Jill S Barnholtz-Sloan; Michael A Tainsky; Judith Abrams; Richard K Severson; Faisal Qureshi; Suzanne M Jacques; Nancy Levin; Ann G Schwartz
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

5.  Survival among U.S. women with invasive epithelial ovarian cancer.

Authors:  Valerie McGuire; Christine A Jesser; Alice S Whittemore
Journal:  Gynecol Oncol       Date:  2002-03       Impact factor: 5.482

6.  Survival of blacks and whites after a cancer diagnosis.

Authors:  Peter B Bach; Deborah Schrag; Otis W Brawley; Aaron Galaznik; Sofia Yakren; Colin B Begg
Journal:  JAMA       Date:  2002-04-24       Impact factor: 56.272

7.  Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States.

Authors:  Linda C Harlan; Limin X Clegg; Edward L Trimble
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

8.  Patterns of chemotherapy use for women with ovarian cancer: a population-based study.

Authors:  Rosemary D Cress; Cynthia D O'Malley; Gary S Leiserowitz; Sharon L Campleman
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.

Authors:  Jill S Barnholtz-Sloan; Ann G Schwartz; Faisal Qureshi; Suzanne Jacques; John Malone; Adnan R Munkarah
Journal:  Am J Obstet Gynecol       Date:  2003-10       Impact factor: 8.661

10.  Health insurance and spending among cancer patients.

Authors:  Kenneth E Thorpe; David Howard
Journal:  Health Aff (Millwood)       Date:  2003 Jan-Jun       Impact factor: 6.301

View more
  74 in total

1.  Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status.

Authors:  Robert E Bristow; Jenny Chang; Argyrios Ziogas; Hoda Anton-Culver; Veronica M Vieira
Journal:  Gynecol Oncol       Date:  2014-03-25       Impact factor: 5.482

2.  Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Authors:  Neil S Horowitz; Austin Miller; Bunja Rungruang; Scott D Richard; Noah Rodriguez; Michael A Bookman; Chad A Hamilton; Thomas C Krivak; G Larry Maxwell
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Racial disparities and patterns of ovarian cancer surgical care in California.

Authors:  F W Liu; L M Randall; K S Tewari; R E Bristow
Journal:  Gynecol Oncol       Date:  2013-09-07       Impact factor: 5.482

4.  Spatial analysis of advanced-stage ovarian cancer mortality in California.

Authors:  Robert E Bristow; Jenny Chang; Argyrios Ziogas; Daniel L Gillen; Lu Bai; Veronica M Vieira
Journal:  Am J Obstet Gynecol       Date:  2015-01-31       Impact factor: 8.661

Review 5.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

6.  Racial and socioeconomic disparities in adherence to preventive health services for ovarian cancer survivors.

Authors:  Lacey Loomer; Kevin C Ward; Evelyn A Reynolds; Silke A von Esenwein; Joseph Lipscomb
Journal:  J Cancer Surviv       Date:  2019-06-06       Impact factor: 4.442

7.  Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.

Authors:  Robert E Bristow; Jenny Chang; Argyrios Ziogas; Belinda Campos; Leo R Chavez; Hoda Anton-Culver
Journal:  J Am Coll Surg       Date:  2015-02-14       Impact factor: 6.113

8.  Variation in insurance status by patient demographics and tumor site among nonelderly adult patients with cancer.

Authors:  Stephen R Grant; Gary V Walker; B Ashleigh Guadagnolo; Matthew Koshy; Pamela K Allen; Usama Mahmood
Journal:  Cancer       Date:  2015-04-27       Impact factor: 6.860

9.  Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.

Authors:  Melissa Hodeib; Jenny Chang; Fong Liu; Argyrios Ziogas; Sarah Dilley; Leslie M Randall; Hoda Anton-Culver; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482

10.  Using Inside Knowledge Campaign Materials to Improve Gynecologic Cancer Knowledge in Underserved Women.

Authors:  Mary Puckett; Julie Townsend; Jenny Rees Patterson; Donna Shaw; Yvonne Wasilewski; Sherri L Stewart
Journal:  J Womens Health (Larchmt)       Date:  2019-08-02       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.